• Spyre Therapeutics held its annual shareholder meeting on May 27, 2026.
• Shareholders adopted an amended and restated 2016 Employee Stock Purchase Plan.
• Shareholders ratified KPMG as independent registered public accounting firm for the year ending Dec. 31, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spyre Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001636282-26-000056), on May 29, 2026, and is solely responsible for the information contained therein.